CELINA SILVIA STAFIE

Dr. CELINA SILVIA STAFIE

UMF ,,Grigore T. Popa"
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
CELINA SILVIA STAFIECELINA SILVIA STAFIE
CELINA SILVIA STAFIE
Irina SufaruIrina Sufaru
Irina Sufaru
CGCristina Mihaela Ghiciuc
Cristina Mihaela Ghiciuc
ISIngrid Ioana Stafie
Ingrid Ioana Stafie
ESEduard-Constantin Sufaru
Eduard-Constantin Sufaru
MHMonica Hancianu
Monica Hancianu
Artificial intelligence (AI) plays a more and more important role in our everyday life due to the advantages that it brings when used, such as 24/7 availability, a very low percentage of errors, ability to provide real time insights, or performing a fast analysis. AI is increasingly being used in clinical medical and dental healthcare analyses, with valuable applications, which include disease diagnosis, risk assessment, treatment planning, and drug discovery. This paper presents a narrative literature review of AI use in healthcare from a multi-disciplinary perspective, specifically in the cardiology, allergology, endocrinology, and dental fields. The paper highlights data from recent research and development efforts in AI for healthcare, as well as challenges and limitations associated with AI implementation, such as data privacy and security considerations, along with ethical and legal concerns. The regulation of responsible design, development, and use of AI in healthcare is still in early stages due to the rapid evolution of the field. However, it is our duty to carefully consider the ethical implications of implementing AI and to respond appropriately. With the potential to reshape healthcare delivery and enhance patient outcomes, AI systems continue to reveal their capabilities.

30 July 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
IMIonela-Larisa Miftode
Ionela-Larisa Miftode
ENEduard Vasile Nastase
Eduard Vasile Nastase
Radu MIFTODERadu MIFTODE
Radu MIFTODE
Egidia MiftodeEgidia Miftode
Egidia Miftode
LILuminița Smaranda Iancu
Luminița Smaranda Iancu
ODOlivia-Simona Dorneanu
Olivia-Simona Dorneanu
The incidence of urinary tract infections (UTIs) caused by Klebsiella pneumoniae has exhibited an increasing trend and has become a high burden for many public health systems, especially in hospital settings. Multidrug resistance associated with the production of extended‑spectrum β‑lactamases (ESBL) among K. pneumoniae isolates is endemic in Southeastern Europe. We retrospectively analyzed 75 cases admitted to ‘St. Parascheva’ Clinical Hospital of Infectious Diseases in Iasi, Romania, during the first 6 months of 2019 (January 1 to June 30), who had a confirmed diagnosis of K. pneumoniae UTI at discharge. From a total of 75 patients, 34 (45.3%) presented ESBL+ K. pneumoniae. The mean age was 66 years (70.1 for the ESBL+ patients vs. 62.6 for the ESBL‑ patients, P=0.0365). There was a symmetrical sex distribution (37 men vs. 38 women). Of these, 22 men had ESBL+ K. pneumoniae UTIs, compared to only 15 with an ESBL‑ strain, P=0.0087. Another risk factor for ESBL+ K. pneumoniae UTIs was the presence of hospitalization in the past 6 months; 20 (58.82%) patients with ESBL+ infections were previously hospitalized, compared to only 5 (12.19%) patients with ESBL‑ strains, P<0.0001. The urinary catheter carriers presented an increased prevalence of ESBL+ infections (15/34 vs. 5/41, P=0.0012). Regarding mortality, ESBL+ infections caused 6 fatalities, compared to only 1 death in the ESBL‑ group, P=0.0166. ESBL+ K. pneumoniae strains represent an important cause of healthcare‑related UTIs, with a significantly higher mortality rate compared to ESBL‑ strains. Early identification and adequate management of the risk factors incriminated in ESBL+ UTIs should be a priority for physicians in order to limit the dissemination of the ESBL‑producing strains and thus to improve the outcome of these patients.

20 January 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
SSSorina Mihaela Solomon
Sorina Mihaela Solomon
Irina SufaruIrina Sufaru
Irina Sufaru
STSilvia Teslaru
Silvia Teslaru
CGCristina Mihaela Ghiciuc
Cristina Mihaela Ghiciuc
CELINA SILVIA STAFIECELINA SILVIA STAFIE
CELINA SILVIA STAFIE
Guided tissue regeneration (GTR) and guided bone regeneration (GBR) became common procedures in the corrective phase of periodontal treatment. In order to obtain good quality tissue neo-formation, most techniques require the use of a membrane that will act as a barrier, having as a main purpose the blocking of cell invasion from the gingival epithelium and connective tissue into the newly formed bone structure. Different techniques and materials have been developed, aiming to obtain the perfect barrier membrane. The membranes can be divided according to the biodegradability of the base material into absorbable membranes and non-absorbable membranes. The use of absorbable membranes is extremely widespread due to their advantages, but in clinical situations of significant tissue loss, the use of non-absorbable membranes is often still preferred. This descriptive review presents a synthesis of the types of barrier membranes available and their characteristics, as well as future trends in the development of barrier membranes along with some allergological aspects of membrane use.

3 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SSSorina Mihaela Solomon
Sorina Mihaela Solomon
CELINA SILVIA STAFIECELINA SILVIA STAFIE
CELINA SILVIA STAFIE
Irina SufaruIrina Sufaru
Irina Sufaru
STSilvia Teslaru
Silvia Teslaru
CGCristina Mihaela Ghiciuc
Cristina Mihaela Ghiciuc
OȚOana Țănculescu
Oana Țănculescu
Scaling and root planing represent the gold standard in the treatment of periodontal disease, but these therapeutic methods cannot eliminate the remaining periodontopathogenic bacteria in cement, tubules, and periodontal soft tissue. Thus, a number of additional therapeutic means have been adopted, including local and systemic antibiotic therapy, as well as the use of photodynamic therapy techniques. Recently, special attention has been paid to potential phytotherapeutic means in the treatment of periodontal disease. In this review, we aim to present the effects generated by the extract of Curcuma longa, the various forms of application of turmeric as an additional therapeutic means, as well as the aspects related to its biotolerance.

8 April 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Mariana FloriaMariana Floria
Mariana Floria
Alexandru OanceaAlexandru Oancea
Alexandru Oancea
PMPaula Cristina Morariu
Paula Cristina Morariu
Alexandru BurlacuAlexandru Burlacu
Alexandru Burlacu
DIDiana-Elena Iov
Diana-Elena Iov
DANIELA MARIA TANASEDANIELA MARIA TANASE
DANIELA MARIA TANASE
Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high β1-selectivity, potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half-life (around 4 min); moreover, it may have a potential therapeutic effects for sepsis and pediatric patients. Landiolol seems to be superior to other short-acting and selective beta-blockers such as esmolol. This review aims to provide a comprehensive overview of landiolol, a new ultra-short-acting β1 selective antagonist, including its pharmacology, clinical applications, efficacy, safety profile, and future directions in research and clinical data.

Verified
Journal Article
Open access
PDF file
ACAdriana Chetran
Adriana Chetran
CELINA SILVIA STAFIECELINA SILVIA STAFIE
CELINA SILVIA STAFIE
OMOvidiu Mitu
Ovidiu Mitu
CCCosmina Elena Ciobanu
Cosmina Elena Ciobanu
DIDan Iliescu-Halițchi
Dan Iliescu-Halițchi
Irina Iuliana COSTACHE-ENACHEIrina Iuliana COSTACHE-ENACHE
Irina Iuliana COSTACHE-ENACHE
Biomarkers are important diagnostic and prognostic tools as they provide results in a short time while still being an inexpensive, reproducible and accessible method. Their well-known benefits have placed them at the forefront of research in recent years, with new and innovative discoveries being implemented. Cardiovascular and neurological diseases often share common risk factors and pathological pathways which may play an important role in the use and interpretation of biomarkers’ values. Among the biomarkers used extensively in clinical practice in cardiology, hs-TroponinT, CK-MB and NTproBNP have been shown to be strongly influenced by multiple neurological conditions. Newer ones such as galectin-3, lysophosphatidylcholine, copeptin, sST2, S100B, myeloperoxidase and GDF-15 have been extensively studied in recent years as alternatives with an increased sensitivity for cardiovascular diseases, but also with significant results in the field of neurology. Thus, given their low specificity, the values interpretation must be correlated with the clinical judgment and other available investigations.